Clinical study on the combination of belimumab and glucocorticoids in the treatment of systemic lupus erythematosus in children

doi:10.11958/20251061

Abstract

Abstract:

Objective To observe the clinical efficacy of belimumab combined with glucocorticoids in the treatment of children with systemic lupus erythematosus (SLE). Methods A total of 64 children with SLE were randomly divided into the observation group and the control group, with 32 cases in each group. The control group was treated with oral prednisone tablets combined with hydroxychloroquine sulfate tablets, while the observation group was treated with belimumab on the basis of treatment in the control group. After 6 months of treatment, the clinical efficacy, systemic lupus erythematosus disease activity index (SLEDAI) scores and laboratory indicators [complement C3, complement C4, immunoglobulin IgG (IgG), B lymphocytes, white blood cell count (WBC), erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), 24-hour urine protein quantification (24 h UP), serum creatinine (SCr) and blood urea nitrogen (BUN)] were compared between the two groups. Results After 6 months of treatment, the total effective rate was higher in the observation group than that of the control group (93.8% vs. 75.0%, P<0.05). Compared with before treatment, both groups showed lower SLEDAI scores, IgG, B lymphocytes, ESR, CRP, SCr, 24 h UP and BUN after treatment, while C3, C4 levels and WBC were higher. Moreover, the improvement of all indicators was better in the observation group than that in the control group (P<0.05). Conclusion Belimumab combined with glucocorticoids can improve the clinical efficacy, control disease activity and enhance immune function in children with SLE.

Key words: lupus erythematosus, systemic, glucocorticoids, inflammation, child, belimumab

CLC Number:

R725.932.4

Figures/Tables 6

References 20

[1]	FANOURIAKIS A, KOSTOPOULOU M, CHEEMA K, et al. 2019 Update of the joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6):713-723. doi:10.1136/annrheumdis-2020-216924.
[2]	谢文慧, 张卓莉. 贝利尤单抗治疗系统性红斑狼疮:现状与展望[J]. 中华风湿病学杂志, 2020, 24(7):495-499.
	XIE W H, ZHANG Z L. Treatment of systemic lupus erythematosus with belizumab:current status and prospects[J]. Chinese Journal of Rheumatology, 2020, 24(7):495-499. doi:10.3760/cma.j.c141217-2019121300420.
[3]	牛吉庆, 彭韶, 储卫红. 贝利尤单抗治疗儿童系统性红斑儿狼疮的疗效和安全性评价[J]. 中国新药与临床杂志, 2023, 42(6):367-372.
	NIU J Q, PENG S, CHU W H. Efficacy and safety of belimumab in treatment of childhood-onset systemic lupus erythematosus[J]. Chinese Journal of New Drugs and Clinical Medicine, 2023, 42(6):367-372. doi:10.14109/j.cnki.xyylc.2023.2023.06.06.
[4]	高雨彤, 何孝亮, 陈登环, 等. 贝利尤单抗治疗儿童系统性红斑狼疮17例临床疗效分析[J]. 临床儿科杂志, 2022, 40(10):745-749.
	GAO Y T, HE X L, CHEN D H, et al. Clinical effect of belizumab on 17 children with systemic lupus erythematosus[J]. Journal of Clinical Pediatrics, 2022, 40(10):745-749. doi:10.12372/jcp.2022.33e0328.
[5]	中华医学会儿科学分会免疫学组,中华儿科杂志编辑委员会. 中国儿童系统性红斑狼疮诊断与治疗指南[J]. 中华儿科杂志, 2021, 59(12):1009-1024.
	Immunology Group,Pediatric Branch of Chinese Medical Association,Editorial Committee of Chinese Journal of Pediatrics. Chinese guidelines for the diagnosis and treatment of childhood-onset systemic lupus erythematosus[J]. Chinese Journal of Pediatrics, 2021, 59(12):1009-1024. doi:10.3760/cma.j.cn112140-20210905-00743.
[6]	GLADMAN D D, IBAÑEZ D, UROWITZ M B. Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002, 29(2):288-291.
[7]	中华医学会儿科学分会风湿病学组,中国医师协会风湿免疫科医师分会儿科学组,海峡两岸医药卫生交流协会风湿免疫病学专业委员会儿童学组, 等. 儿童系统性红斑狼疮临床诊断与治疗专家共识(2022版)[J]. 中华实用儿科临床杂志, 2022, 37(9):641-652.
	The Rheumatology Group of the Pediatrics Branch of the Chinese Medical Association,the Pediatrics Group of the Rheumatology and Immunology Branch of the Chinese Medical Association,and the Children's Group of the Rheumatology and Immunology Professional Committee of the Cross Strait Medical and Health Exchange Association. Expert consultation on clinical diagnosis and treatment of childhood systemic lupus erythematosus(2022 version)[J]. Chinese Journal of Practical Pediatrics, 2022, 37(9):641-652. doi:10.3760/cma.j.cn101070-20220321-00295.
[8]	李桂女, 任少琳, 沈瑞明, 等. 二甲双胍联合糖皮质激素治疗伴糖耐量异常的系统性红斑狼疮患者的临床研究[J]. 中国临床药理学与治疗学, 2020, 25(6):670-676.
	LI G N, REN S L, SHEN R M, et al. Clinical study of metformin combined with glucocorticoids in the treatment of systemic lupus erythematosus patients with impaired glucose tolerance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6):670-676. doi:10.12092/j.issn.1009-2501.2020.06.010.
[9]	张俊霞, 时利玲, 柴焕然, 等. 白芍总苷胶囊联合泼尼松片对儿童系统性红斑狼疮的疗效观察[J]. 临床研究, 2023, 31(1):107-110.
	ZHANG J X, SHI L L, CHAI H R, et al. Observation on the therapeutic effect of total glucosides of paeony capsule combined with prednisone tablets on children with systemic lupus erythematosus[J]. Clinical Research, 2023, 31(1):107-110. doi:10.12385/j.issn.2096-1278(2023)01-0107-04.
[10]	罗颖婷, 黄家敏. 羟氯喹联合环孢素治疗系统性红斑狼疮并顽固性血小板减少效果及安全性分析[J]. 北方药学, 2020, 17(7):175-176.
	LUO Y T, HUANG J M. Analysis of the efficacy and safety of hydroxychloroquine combined with cyclosporine in the treatment of systemic lupus erythematosus with refractory thrombocytopenia[J]. Northern Pharmaceutical Journal, 2020, 17(7):175-176. doi:10.3969/j.issn.1672-8351.2020,07.130.
[11]	吴琼, 李正一, 丁显春. 贝利尤单抗治疗儿童系统性红斑狼疮的效果观察[J]. 临床医学工程, 2022, 29(5):645-646.
	WU Q, LI Z Y, DING X C. Observation on the effect of belizumab in the treatment of children with systemic lupus erythematosus[J]. Clinical Medical Engineering, 2022, 29(5):645-646. doi:10.3969/j.issn.1674-4659.2022.05.0645.
[12]	DIMELOW R, JI B, STRUEMPER H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus[J]. Clin Pharmacol Drug Dev, 2021, 10(6):622-633. doi:10.1002/cpdd.889.
[13]	JIANG Y, SUN J, WEI J. Distinct binding mode of BAFF antagonist antibodies belimumab and tabalumab,analyzed by computer simulation[J]. J Mol Model, 2022, 28(10):292. doi:10.1007/s00894-022-05142-7.
[14]	王倩涵, 苗永红, 安乐美. 小样本应用贝利尤单抗治疗儿童系统性红斑狼疮的临床疗效观察[J]. 中国中西医结合儿科学, 2023, 15(2):137-141.
	WANG Q H, MIAO Y H, AN L M. Clinical efficacy of beribizumab in a small sample of children with systemic lupus erythematosus[J]. Chin PediatrIntegr Tradit West Med, 2023, 15(2):137-141. doi:10.3969/j.issn.1674-3865.2023.010.
[15]	吴春叶, 邢钧, 龚宝琪. 贝利尤单抗治疗初发系统性红斑狼疮的短期疗效观察[J]. 天津医药, 2023, 51(7):771-775.
	WU C Y, XING J, GONG B Q. Short-term clinical efficacy observation of belizumab in the treatment of primary systemic lupus erythematosus[J]. Tianjin Med J, 2023, 51(7):771-775. doi:10.11958/20221006.
[16]	韩敬, 顾津伊, 刘裔, 等. 血清中性粒细胞胞外诱捕网水平与狼疮性肾炎的相关性[J]. 天津医药, 2022, 50(2):171-176.
	HAN J, GU J Y, LIU Y, et al. Study on the correlation between serum neutrophil extracellular trap level and lupus nephritis[J]. Tianjin Med J, 2022, 50(2):171-176. doi:10.11958/20211707.
[17]	BRUNNER H I, ABUD-MENDOZA C, VIOLA D O, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus:results from a randomised,placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(10):1340-1348. doi:10.1136/annrheumdis-2020-217101.
[18]	邓伟萍, 胡长平, 罗平. 贝利尤单抗用于儿童系统性红斑狼疮的研究进展[J]. 中国当代儿科杂志, 2021, 23(10):1069-1074.
	DENG W P, HU C P, LUO P. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children[J]. Chinese Journal of Contemporary Pediatrics, 2021, 23(10):1069-1074.
[19]	李思佳. 糖皮质激素联合环磷酰胺治疗系统性红斑狼疮的效果及对患者炎性因子水平、免疫功能指标和肾功能指标的影响[J]. 临床医学研究与实践, 2021, 6(32):72-74.
	LI S J. Effect of glucocorticoid combined with cyclophosphamide in the treatment of systemic lupus erythematosus and its influence on inflammatory factors level, immune function indexes and renal function indexes[J]. Clinical Medical Research and Practice, 2021, 6(32):72-74. doi:10.19347/j.cnki.2096-1413.202132023.
[20]	亚太医学生物免疫学会儿童过敏免疫风湿病分会(PAIRB-APAMBI)多中心研究协作组,《中国实用儿科杂志》编辑委员会. 贝利尤单抗治疗中国儿童系统性红斑狼疮28周有效性和安全性分析:一项回顾性多中心真实世界的初步研究[J]. 中国实用儿科杂志, 2021, 36(11):858-868.
	The Multicenter Research Collaborative Group of the Pediatric Allergy,Immunology,and Rheumatology Branch of the Asia Pacific Medical Bioimmunology Society(PAIRB-APAMBI),Editorial Committee of the Chinese Journal of Practical Pediatrics. Efficacy and safety analysis of belimumab for 28 weeks in real-world Chinese children with systemic lupus ery-thematosus:a retrospective multicenter pilot study[J]. Chinese Journal of Practical Pediatrics, 2021, 36(11):858-868. doi:10.19538/j.ek2021110612.

组别	性别				年龄/岁		病程/月
组别	男		女		年龄/岁		病程/月
对照组	8（25.0）		24（75.0）		12.02±3.16		8.45±2.73
观察组	7（21.9）		25（78.1）		11.65±3.10		7.86±2.12
χ²或t	0.087				0.473		0.966
组别		疾病活动度				SLEDAI-2K评分/分
组别		中度		重度		SLEDAI-2K评分/分
对照组		19（59.4）		13（40.6）		12.05±2.22
观察组		17（53.1）		15（46.9）		11.54±2.16
χ²或t		0.500				0.931

组别	性别				年龄/岁		病程/月
组别	男		女		年龄/岁		病程/月
对照组	8（25.0）		24（75.0）		12.02±3.16		8.45±2.73
观察组	7（21.9）		25（78.1）		11.65±3.10		7.86±2.12
χ²或t	0.087				0.473		0.966
组别		疾病活动度				SLEDAI-2K评分/分
组别		中度		重度		SLEDAI-2K评分/分
对照组		19（59.4）		13（40.6）		12.05±2.22
观察组		17（53.1）		15（46.9）		11.54±2.16
χ²或t		0.500				0.931

组别	显效	有效	无效	总有效
对照组	11（34.4）	13（40.6）	8（25.0）	24（75.0）
观察组	16（50.0）	14（43.8）	2（6.2）	30（93.8）
χ²				4.267^＊

组别	显效	有效	无效	总有效
对照组	11（34.4）	13（40.6）	8（25.0）	24（75.0）
观察组	16（50.0）	14（43.8）	2（6.2）	30（93.8）
χ²				4.267^＊

组别	治疗前	治疗后	t
对照组	12.05±2.22	7.56±1.72	6.005^＊＊
观察组	11.54±2.16	5.27±1.24	9.717^＊＊
t	0.931	6.109^＊＊